# US 2015/0031609 A1 · Methods and compositions for delivering peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031609 A1
- Document ID: US20150031609A1
- Status: Published application
- Kind: A1
- Application number: 14/513,111
- Filed: 2014-10-13
- Published: 2015-01-29
- Earliest claimed: 1999-06-29
- Assignees: MannKind Corporation
- Applicants: MannKind Corporation
- Inventors: Solomon S. Steiner; Rodney J. Woods; Joseph W. Sulner
- Web page: https://patentgrep.com/patent/US20150031609A1

## CPC

- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/145: {with organic compounds}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 38/28: Insulins
- A61K 47/6949: {inclusion complexes, e.g. clathrates, cavitates or fullerenes}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07D 241/08: with oxygen atoms directly attached to ring carbon atoms
- C07K 1/30: by precipitation
- C07K 1/32: as complexes
- C07K 14/605: Glucagons
- C07K 14/62: Insulins
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery.

## Claims

### Claim 1

A microparticle composition comprising microparticles containing a diketopiperazine and at least one of a peptide and a protein, wherein the microparticle composition is prepared by a method comprising forming at least a portion of the microparticles containing the diketopiperazine in the absence of at least one of the peptide and the protein.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the microparticles containing the diketopiperazine comprise fumaryl diketopiperazine.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the peptide or the protein is an insulin.

### Claim 4 (depends on 3)

A method of delivering an insulin to a patient in need thereof, comprising administering the composition of claim 3 to the patient.

### Claim 5

A composition comprising microparticles of a diketopiperazine and at least one of a peptide and a protein, wherein the composition comprising microparticles of the diketopiperazine is prepared by a method comprising forming microparticles of the diketopiperazine from an aqueous solution that does not include at least one of the peptide and the protein.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the diketopiperazine is fumaryl diketopiperazine.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the peptide or the protein comprises an insulin.

### Claim 8 (depends on 7)

A method of treating diabetes, comprising administering a composition of claim 7 to a diabetic patient in need of treatment.

### Claim 9

Peptide or protein-loaded diketopiperazine microparticles prepared by a process comprising adding the peptide or protein to a suspension comprising microparticles of a diketopiperazine.

### Claim 10 (depends on 9)

The peptide or protein-loaded microparticles of claim 9, wherein the microparticles comprise fumaryl diketopiperazine.

### Claim 11 (depends on 9)

The peptide or protein-loaded microparticles of claim 9, wherein the microparticles comprise an insulin.

### Claim 12 (depends on 9)

The peptide or protein-loaded microparticles of claim 9, wherein solvent is removed by lyophilization from the suspension comprising the peptide or protein and microparticles of the diketopiperazine.

### Claim 13 (depends on 9)

A method of pulmonary delivery of a protein or a peptide to a mammal in need thereof, the method comprising administering the peptide or protein-loaded microparticles of claim 9 to the mammal by inhalation.
